NCT00861484

Proof of Mechanism in ELT

A Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of a Single Oral Dose of GSK958108 on Ejaculatory Latency Time (ELT) in Male Patient Suffering From Premature Ejaculation

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 33 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: Male
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if the administration of GSK958108 can delay ejaculation in patients with primary premature ejaculation as measured by the ejaculatory latency time (ELT) using the masturbation model and sexual visual stimulation, and to evaluate the safety and tolerability of GSK958108 in healthy men with PE

Conditions

• Premature Ejaculation

Interventions

Type	Name	Description
DRUG	GSK958108	Coated Tablets 1 mg
DRUG	Placebo	Coated tablets

Timeline

• Start date: 2008-11-26
• Primary completion: 2009-12-11
• Completion: 2009-12-11
• First posted: 2009-03-13
• Last updated: 2017-06-14

Locations

1 site across 1 country: Italy